Table 2 Clinical trials of CD3+ bispecific T-cell redirectors for haematological cancers.
From: Overcoming the challenges associated with CD3+ T-cell redirection in cancer
Targets | Clinical trial Phase | Clinical trial identifier | Disease indication(s) | Organisation(s) | Antibody |
|---|---|---|---|---|---|
CD3 × CD19 | Launched | NCT01207388 | B-cell precursor ALL | Amgen | Blinatumomab; Blincyto; AMG 103 |
CD3 × CD19 | Phase 1 | NCT03571828 | B-cell NHL; DLBCL; MCL; FL | Amgen | AMG 562 |
CD3 × CD19 | Phase 1 | NCT04056975 | B-cell lymphoma | Generon | A-319 |
CD3 × CD19 | Phase 1 | CTR20191955 | B-cell lymphoma | Lvzhu Biopharmaceutical | K193 |
CD3 × CD20 | Phase 1/2 | NCT02651662 NCT02290951 NCT03888105 | B-cell NHL; CLL | Regeneron | REGN1979 |
CD3 × CD20 | Phase 1 | NCT04082936 | B-cell NHL; DLBCL; MCL; FL; MZL | IGM Biosciences | IGM-2323 |
CD3 × CD20 | Phase 1 | NCT02924402 | B-cell NHL; CLL; small lymphocytic lymphoma | Xencor | Plamotamab; XmAb13676 |
CD3 × CD20 | Phase 1/2 | NCT02500407 NCT03671018 NCT03677141 NCT03677154 | B-cell NHL; CLL; DLBCL | Genentech; Hoffmann-La Roche | Mosunetuzumab; BTCT4465A; RO7030816 |
CD3 × CD20 | Phase 1/2 | NCT03625037 | DLBCL; MCL; FL | Genmab | GEN3013 |
CD3 × CD20 | Phase 1 | NCT03075696 NCT03533283 NCT04313608 NCT04246086 NCT04077723 NCT03467373 | B-cell NHL; DLBCL; FL | Hoffmann-La Roche | Glofitamab; RO7082859 |
CD3 × CD20 | Phase 1 | NCT00244946 NCT00938626 | B-cell NHL; multiple myeloma; plasma cell neoplasm | Barbara Ann Karmanos Cancer Institute | CD20Bi-ATC |
CD3 × CD33 | Phase 1 | NCT03915379 | Myelodysplastic syndrome; AML | Janssen | JNJ-67571244 |
CD3 × CD33 | Phase 1 | NCT02520427 | Myelodysplastic syndrome; AML | Amgen | AMG 330 |
CD3 × CD33 | Phase 1 | NCT03224819 | AML | Amgen | AMG 673 |
CD3 × CD33 | Phase 1 | NCT03516760 | AML | Celgene | GEM333 |
CD3 × CD33 | Phase 1 | NCT04128423 NCT03144245 NCT03516591 | Myelodysplastic syndrome; AML | Amphivena Therapeutics | AMV564 |
CD3 × CD38 | Phase 1/2 | NCT03309111 | Multiple myeloma | Glenmark Pharmaceuticals | GBR 1342 |
CD3 × CD38 | Phase 1 | NCT03445663 | Multiple myeloma | Amgen | AMG 424 |
CD3 × CD123 | Phase 1 | NCT03647800 | Myelodysplastic syndrome; AML | Aptevo Therapeutics | APVO436 |
CD3 × CD123 | Phase 1/2 | NCT04158739 NCT02152956 NCT03739606 | AML; ALL; other haematologic malignancies | MacroGenics | Flotetuzumab; MGD006 |
CD3 × CD123 | Phase 1 | NCT02730312 | B-cell ALL; AML; CLL; blastic plasmacytoid dendritic cell neoplasm | Xencor | Vibecotamab; XmAb14045 |
CD3 × CD123 | Phase 1/2 | NCT03594955 | B-cell ALL; AML; myelodysplastic syndrome | Sanofi | SAR440234 |
CD3 × CD123 | Phase 1 | NCT02715011 | AML | Janssen | JNJ-63709178 |
CD3 × BCMA | Phase 1 | NCT02514239 NCT03836053 | Multiple myeloma | Boehringer Ingelheim; Amgen | BI 836909; AMG 420 |
CD3 × BCMA | Phase 1 | NCT03287908 | Multiple myeloma | Amgen | AMG 701 |
CD3 × BCMA | Phase 1 | NCT03933735 | Multiple myeloma | AbbVie; TeneoBio | TNB-383B |
CD3 × BCMA | Phase 1 | NCT03269136 | Multiple myeloma | Pfizer | PF-06863135 |
CD3 × BCMA | Phase 1 | NCT03145181 NCT04108195 | Multiple myeloma | Janssen | JNJ-64007957 |
CD3 × BCMA | Phase 1 | NCT03486067 | Multiple myeloma | Celgene | CC-93269 |
CD3 × BCMA | Phase 1/2 | NCT03761108 | Multiple myeloma | Regeneron; Sanofi | REGN5458 |
CD3 × BCMA | Phase 1 | NCT04083534 | Multiple myeloma | Regeneron; Sanofi | REGN5459 |
CD3 × BCMA × ALB | Phase 1/2 | NCT04184050 | Multiple myeloma | Harpoon Therapeutics; AbbVie | HPN217 |
CD3 × CLEC12A | Phase 1 | NCT03038230 | AML | Merus | Tepoditamab; MCLA-117 |
CD3 × FcRH5 | Phase 1 | NCT03275103 | Multiple myeloma | Genentech | RO7187797; BFCR4350A |
CD3 × FLT3 | Phase 1 | NCT03541369 | AML | Amgen | AMG 427 |
CD3 × GPRC5D | Phase 1 | NCT03399799 NCT04108195 | Multiple myeloma | Janssen | JNJ-64407564 |
